#United States #Tampa #PainTEQ #ASPN #TRAQ

PainTEQ Unveils Groundbreaking Evidence at ASPN 2026

In an exciting revelation for the medical community, PainTEQ, a frontrunner in minimally invasive pain management, presented revolutionary findings at the American Society of Pain and Neuroscience (ASPN) 2026 Annual Conference. These findings shed light on the efficacy of posterior fixation procedures for addressing sacroiliac joint dysfunction, a condition affecting numerous patients.

Key Presentations

During ASPN 2026, the spotlight was on several presentations, notably the PainTEQ Real-world Anatomical Data Analysis (PRADA) Study. This significant study marks the first extensive CT-based evaluation of sacroiliac joint cortical bone thickness. Researchers utilized advanced high-resolution CT imaging techniques to ascertain that the TRAQ™ procedure's 2.5 mm cortical-piercing fixation ridges not only exceeded the maximum cortical thickness observed but consistently penetrated the cortical bone of both the sacrum and ilium across diverse demographic groups.

Dr. Doug Beall, a prominent figure in the medical panel, expressed enthusiasm over these findings: "The PRADA Study offers crucial anatomical proof for the TRAQ cortical-piercing fixation strategy. With the fixation ridges exceeding the established maximum cortical thickness, it’s confirmed that TRAQ effectively engages both the sacral and iliac regions across various patient anatomies."

Biomechanical Evidence

Adding further strength to PainTEQ's narrative, complementary finite element analyses indicated that both the LINQ® and TRAQ™ procedures exhibited superior resistance to micromotion, alongside improved fixation characteristics when compared to commonly used posterior implant designs. This body of complementary anatomical and biomechanical data provides a robust case for the efficacy of posterior fixation strategies, supporting both the sacral and iliac cortices.

In addition to biomechanical evaluations, real-world experiences shared by investigators highlighted the TRAQ procedure's significant potential. A multicenter analysis involving 154 patients across 61 clinical sites reported no device- or procedure-associated adverse events during the initial release phase, alongside promising improvements in pain as reported by patients.

Dr. Dawood Sayed remarked on the convergence of anatomical research, biomechanics, and real-world clinical data, emphasizing how this synchronization fosters increased confidence in the fixation strategy underlying the TRAQ procedure. "When various facets of research align, as demonstrated in these studies, it solidifies the case for posterior sacroiliac joint procedures," he noted.

Further Research and Commitment

Additional presentations supported by PainTEQ at the conference included a podium comparison of posterior versus lateral minimally invasive sacroiliac joint procedures using propensity-matched analyses, alongside biomechanical research enhancing posterior fixation comprehension. Together, these collaborative efforts expand the existing framework of evidence for posterior sacroiliac joint procedures, reinforcing PainTEQ’s leadership in the field.

This recent scientific exposition aligns seamlessly with PainTEQ's commitment to advancing clinical knowledge, enhancing physician education on sacroiliac joint dysfunction treatments, and fostering high-quality clinical evidence for enhanced patient care.

About PainTEQ

Founded in 2013 and headquartered in Tampa, Florida, PainTEQ is at the forefront of developing innovative, minimally invasive solutions for chronic pain relief. The company’s commitment to clinical excellence and evidence-based innovation empowers healthcare providers to expand treatment options for patients suffering from chronic pain. For more details, visit www.painteq.com.